Mediwound Ltd
NASDAQ:MDWD

Watchlist Manager
Mediwound Ltd Logo
Mediwound Ltd
NASDAQ:MDWD
Watchlist
Price: 16.48 USD -1.67% Market Closed
Market Cap: 177.8m USD
Have any thoughts about
Mediwound Ltd?
Write Note

Mediwound Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mediwound Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Mediwound Ltd
NASDAQ:MDWD
Interest Income Expense
-$4.6m
CAGR 3-Years
-67%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Interest Income Expense
-$1B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-13%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Interest Income Expense
$1.8m
CAGR 3-Years
66%
CAGR 5-Years
6%
CAGR 10-Years
N/A
I
InterCure Ltd
TASE:INCR
Interest Income Expense
-â‚Ş23.8m
CAGR 3-Years
N/A
CAGR 5-Years
-66%
CAGR 10-Years
-17%
S
Seach Medical Group Ltd
TASE:SEMG
Interest Income Expense
-â‚Ş2.2m
CAGR 3-Years
N/A
CAGR 5-Years
-27%
CAGR 10-Years
N/A
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Interest Income Expense
-â‚Ş9m
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
-3%
No Stocks Found

Mediwound Ltd
Glance View

Market Cap
177.8m USD
Industry
Pharmaceuticals

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

MDWD Intrinsic Value
10.47 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Mediwound Ltd's Interest Income Expense?
Interest Income Expense
-4.6m USD

Based on the financial report for Jun 30, 2024, Mediwound Ltd's Interest Income Expense amounts to -4.6m USD.

What is Mediwound Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-21%

Over the last year, the Interest Income Expense growth was -1%. The average annual Interest Income Expense growth rates for Mediwound Ltd have been -67% over the past three years , -21% over the past five years .

Back to Top